Management of French patients with type 2 diabetes mellitus in medical general practice: Report of the Mediab observatory

Diabetes and Metabolism

Volumn 30, Issue 1, 2004, Pages 35-42

  Monnier, L ^a   Grimaldi, A ^b   Charbonnel, B ^c   Iannascoli, F ^d   Lery, T ^d   Garofano, A ^e   Childs, M ^e  

^a LAPEYRONIE HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d NOVO NORDISK A S   (Denmark)

^e Mediscan Society   (France)

Author keywords

Monitoring in general practice; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN SENSITIZING AGENT; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BEHAVIOR MODIFICATION; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE DURATION; FEMALE; FRANCE; GENERAL PRACTICE; GLUCOSE BLOOD LEVEL; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDIAB OBSERVATORY; MEDICAL PRACTICE; METHODOLOGY; MONITORING; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORP METHODOLOGY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PREVALENCE;

EID: 1842611399     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70087-3     Document Type: Article

References (32)

1. Blazy D, Nguyen M. La population diabétique en France. Diab Metab, 1993, 19, 483-90.
2. Le Floch JP, Thervet F, Desriac I, Boyer JF, Simon D. Management of diabetic patients by general practitioners in France 1997: an epidemiological study. Diabetes Metab, 2000, 26, 43-9.
3. Detournay B, Cros S, Charbonnel B, et al. Managing type 2 diabetes in France: The Ecodia Survey. Diabetes Metab, 2000, 26, 363-9.
4. Vauzell-Kervroëdan, Cherou-Debregas S, Forman A, Fender P, Eschwege E. Le diabète de type II pris en charge à 100% en 1994: caractéristiques et suivi. Diabetes Metab, 2000, 26, 55-62.
5. Recommandations de l'ANAES. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications. Diabetes Metab, 1999, 25, 1-64.
6. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care, 2002, 25, S33-S49.
7. Delcourt C, Papoz L. Les complications dégéné ratives du diabète non insulino-dépendant. L'étude CODIAB. In: Le diabète et ses complications dans la population française. C. DELCOURT, L. PAPOZ Eds. Editions INSERM, Paris. 1996, 53-77.
8. Delcourt C, Vauzelle-Kervroëdan F, Cathelineau G, Papoz L and The Codiab-Inserm-Zeneca Pharma Study Group. Low prevalence of long-term complications in non-insulin-dependent diabetes mellitus in France: a multicenter study. J of Diabetes and its Complications, 1998, 12, 88-95.
9. Childs M, Cayet J, Desnoyers E, Lagente JL. Les observatoires de la prise en charge du patient atteint d'une pathologie (ORP®). Vers l'établissement de nouveaux standards méthodologiques. La Lettre du Pharmacologue, 1999, 13, 90-2.
10. th Edition Prentice-Hall Inc, New Jersey USA. 1999, 663.
11. e édition. Masson Eds, Paris. 1998, 332.
12. Balkau B, Eschwege E. Risk factors and their identification second part: study design for identification of risk factors. Diab Metab, 1995, 21, 225-31.
13. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care, 1997, 20, 725-34.
14. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diab Rev, 1997, 5, 294-315.
15. Anderson DKG, Svärdsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care, 1995, 18, 1535-43.
16. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 1995, 18, 258-68.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 854-65.
18. Feinglos MN, Bethel NA. Oral agent therapy in the treatment of type 2 diabetes. Diabetes Care, 1999, 22, C61-C64.
19. Buse JB. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy. Diabetes Care, 1999, 22, C65-C70.
20. McNabb WL. Adherence in diabetes: Can we define it and can we measure it? Diabetes Care, 1997, 20, 215-8.
21. Beckles GLA, Engelgau MM, Narayan KMV, Herman WH, Aubert RE, Williamson DE. Population-based assessment of the level of care among adults with diabetes in the U.S. Diabetes Care, 1998, 21, 1432-8.
22. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care, 1997, 20, 1744-66.
23. Monnier L, Colette C, Avignon A, Percheron C, Lapinski M, Boniface H. Le changement dans la prise en charge diététique du diabétique. Diabetes Metab, 1998, 24, 24-34.
24. Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care, 2002, 25, 148-98.
25. Franz MJ, Monk A, Barry B, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc, 1995, 95, 1009-17.
26. Weill A, Ricordeau P, Vallier N, Bourret R, Fender P, Allemand H. Les modalités de suivi des diabétiques non insulinotraités en France métropolitaine durant l'année 1998. Diabetes Metab, 2000, 26, 39-48.
27. Harris M, Klein P, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis; Diabetes Care, 1992, 15, 815-9.
28. Stratton IM, Adler AI, Neil HAW, et al. On behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321, 405-12.
29. Adler AI, Stratton IM, Neil HAW, et al. On behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321, 412-9.
30. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2002, 25, S74-S77.
31. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998, 339, 229-34.
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protective Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-22.